Antihypertensive therapy in the obese hypertensive patient

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 5, 2006, Pages 487-492

  Chrostowska, Marzena ^a   Szczȩch, Radosław ^a   Narkiewicz, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Antihypertensive therapy; Cardiac risk factors; Hypertension; Obesity; Sleep apnea

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; HYPOKALEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY INJURY; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; OBESITY; SLEEP APNEA, OBSTRUCTIVE; WEIGHT LOSS;

EID: 33747350003     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000242173.14082.dc     Document Type: Review

References (48)

1. Haslam DW, James WP. Obesity. Lancet 2005; 366:1197-1209. An excellent review presenting the epidemiology, pathophysiology, consequences and management of obesity.
2. Poirier P, Giles TD, Bray GA, et al. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss - an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113:898-918. This is an important summary of the evidence linking obesity to cardiovascular disease with clinical implications for both specialists and primary care physicians.
3. Narkiewicz K. Obesity and hypertension: the issue is more complex than we thought. Nephrol Dial Transplant 2006; 21:264-267.
4. Poirier P, Lemieux I, Mauriege P, et al. Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension 2005; 45:363-367. Elegant study demonstrating that the association between obesity and blood pressure is largely explained by concomitant variation in waist circumference.
5. Mamun AA, Lawlor DA, O'Callaghan MJ, Williams GM, et al. Effect of body mass index changes between ages 5 and 14 on blood pressure at age 14: findings from a birth cohort study. Hypertension 2005; 45:1083-1087. This interesting study highlighted the important role of weight changes in the development and maintenance of hypertension in children and adolescents.
6. Thomas F, Bean K, Pannier B, et al. Cardiovascular mortality in overweight subjects: the key role of associated risk factors. Hypertension 2005; 46:654-659. This article provides evidence that hypertension is a putative mechanism through which obesity may cause cardiovascular disease.
7. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45:9-14. An excellent review discussing the novel mechanisms linking obesity to hypertension.
8. Bełtowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006; 24:789-801. A comprehensive review presenting current knowledge about the role of leptin in the regulation of blood pressure and in the pathogenesis of arterial hypertension.
9. Wofford MR, Hall JE. Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004; 10:3621-3637.
10. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43:41-47.
11. Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 2005; 46:1316-1320. This elegant study explored the role of angiotensin II in the regulation of renal circulation.
12. Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens 2006; 15:173-178. An excellent review discussing the consequences of accumulation of 'dysfunctional' adipose tissue characterized by the presence of 'large' adipocytes.
13. Rahmouni K, Morgan DA, Morgan GM, et al. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005; 54:2012-2018. Elegant animal study exploring the hypothesis of selective leptin resistance with important implications for diet-induced obesity hypertension.
14. Ribeiro MM, Silva AG, Santos NS, et al. Diet and exercise training restore blood pressure and vasodilatory responses during physiological maneuvers in obese children. Circulation 2005; 111:1915-1923. Obesity exacerbates blood pressure responses and impairs vasodilatory responses during exercise and mental stress in obese children; the alterations might be reversed by diet and exercise training.
15. Maple-Brown LJ, Piers LS, O'Rourke MF, et al. Central obesity is associated with reduced peripheral wave reflection in Indigenous Australians irrespective of diabetes status. J Hypertens 2005; 23:1403-1407.
16. Whincup PH, Gilg JA, Donald AE, et al. Arterial distensibility in adolescents: the influence of adiposity, the metabolic syndrome, and classic risk factors. Circulation 2005; 112:1789-1797.
17. Zebekakis PE, Nawrot T, Thijs L, et al. Obesity is associated with increased arterial stiffness from adolescence until old age. J Hypertens 2005; 23:1839-1846. This well designed study demonstrated differential influence of adiposity on the properties of muscular and elastic arteries.
18. Cassidy AE, Bielak LF, Zhou Y, et al. Progression of subclinial coronary atherosclerosis: does obesity make a difference? Circulation 2005; 111:1877-1882.
19. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 2005; 30:1-10.
20. Masuo K, Katsuya T, Fu Y, et al. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 2005; 111:3429-3434. This study highlighted the important role of genetic factors in the development of obesity-related hypertension.
21. Narkiewicz K, Wolf J, Lopez-Jimenez F, Somers VK. Obstructive sleep apnea and hypertension. Curr Cardiol Rep 2005; 7:435-440. A short but informative review presenting current concepts regarding pathogenesis of obstructive sleep apnea and its role in obesity-related hypertension.
22. Baguet JP, Narkiewicz K, Mallion JM. Update on hypertension management: obstructive sleep apnea and hypertension. J Hypertens 2006; 24:205-208. Recent update on management and treatment of obstructive sleep apnea with important implications for obesity-related hypertension resistant to treatment.
23. Haas DC, Foster GL, Nieto FJ, et al. Age-dependent associations between sleep-disordered breathing and hypertension: importance of discriminating between systolic/diastolic hypertension and isolated systolic hypertension in the Sleep Heart Health Study. Circulation 2005; 111:614-621.
24. Baguet JP, Hammer L, Levy P, et al. Night-time and diastolic hypertension are common and underestimated conditions in newly diagnosed apnoeic patients. J Hypertens 2005; 23:521-527. An important study indicating that ambulatory blood pressure monitoring might be of particular significance in the diagnosis of obese hypertensive people with obstructive sleep apnea.
25. Aucott L, Poobalan A, Smith WC, et al. Effects of weight loss in overweight/ obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005; 45:1035-1041. A systematic review of randomized controlled trials indicating that extrapolation of short-term blood pressure changes with weight loss to the longer term is potentially misleading.
26. Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45:356-362. This excellent study is the first to show that even modest reduction in body weight can lead to a meaningful reduction in renin-angiotensin-aldosterone system activity in adipose tissue.
27. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20:1873-1878.
28. Jordan J, Scholze J, Matiba B, et al. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord 2005; 29:509-516.
29. Sharma AM. Does pharmacologically induced weight loss improve cardiovascular outcome? Sibutramine pharmacology and the cardiovascular system. Eur Heart J Supplements 2005; 7 (Suppl L):L5-L10.
30. Despres JP,Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-2134.
31. Sjostrom L, Lindroos AK, Peltonen M, et al., Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683-2693.
32. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001; 19:667-674.
33. Reisin E, Weir MR, Falkner B, et al., Treatment in Obese Patients with Hypertension (TROPHY) Study Group. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertension 1997; 30:140-145.
34. de Simone G, Wachtell K, Palmieri V, et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation 2005; 111:1924-1931. Post-hoc analysis of the LIFE study looking for possible differential effects of antihypertensive treatments in obese versus nonobese participants.
35. Dahlof B, Sever PS, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. The article indicates that the antihypertensive regimen of amlodipine (adding perindopril as required) might prevent more major cardiovascular events than atenolol (adding bendroflumethiazide as required) in both nonobese and obese subjects.
36. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354:1685-1697. The study investigated whether pharmacologic treatment of prehypertension might prevent or postpone development of sustained hypertension.
37. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
38. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165:742-748.
39. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004; 44:12-19.
40. Ruilope LM, Rosei EA, Bakris GL, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 2005; 14:196-209. This is a detailed review of the recent trials with angiotensin receptor blockers focusing on their favorable metabolic properties and end-organ protection.
41. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23:463-473. Elegant review including meta-analysis with important implications for treatment of hypertensive people at risk of development of diabetes.
42. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46:821-826.
43. Jordan J, Engeli S, Boschmann M, et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens 2005; 23:2313-2318. This head-to-head study compared blood pressure and metabolic responses to treatment with valsartan and atenolol in obese hypertensive patients.
44. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21:1761-1769.
45. Schupp M, Janke J, Clasen, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109:2054-2057.
46. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46:137-143. Interesting study exploring novel mechanism responsible for insulin-sensitizing/ antidiabetic effects of PPARgamma-activating angiotensin type-1 receptor blockers.
47. Sugimoto K, Qi NR, Kazdova L, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47:1003-1009. This study raises the possibility that certain angiotensin II receptor blockers may have a particularly strong impact on fat cell volume and fat accumulation, as well as distinctive effects on energy metabolism.
48. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004; 17:904-910.